Overview

Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin

Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Phase 2 evaluation of capecitabine in patients with advanced or recurrent squamous cell carcinoma of the skin.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborator:
National Cancer Institute (NCI)
Treatments:
Capecitabine